NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of “Buy” by Brokerages
NeoGenomics, Inc. (NASDAQ:NEO) has been assigned a consensus recommendation of “Buy” from the eleven analysts that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $20.63.
A number of brokerages have commented on NEO. Zacks Investment Research downgraded shares of Hallmark Financial Services from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective (down from $15.00) on shares of Nabriva Therapeutics in a research report on Wednesday, May 1st. Finally, BidaskClub downgraded shares of Westport Fuel Systems from a “buy” rating to a “hold” rating in a research report on Friday, July 19th.
In related news, Director Raymond R. Hipp sold 150,000 shares of the stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $22.41, for a total value of $3,361,500.00. Following the transaction, the director now directly owns 256,059 shares of the company’s stock, valued at approximately $5,738,282.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider William Bonello sold 7,200 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $23.53, for a total transaction of $169,416.00. Following the completion of the transaction, the insider now directly owns 13,935 shares in the company, valued at $327,890.55. The disclosure for this sale can be found here. Over the last three months, insiders sold 338,876 shares of company stock worth $7,674,362. Insiders own 8.80% of the company’s stock.
NeoGenomics stock traded down $0.42 during mid-day trading on Tuesday, reaching $23.88. 150,246 shares of the company’s stock were exchanged, compared to its average volume of 590,578. The firm has a market capitalization of $2.32 billion, a P/E ratio of 182.00 and a beta of 0.78. NeoGenomics has a twelve month low of $11.05 and a twelve month high of $24.84. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.35. The stock’s fifty day simple moving average is $23.02.
NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, April 30th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.03. NeoGenomics had a negative net margin of 0.14% and a positive return on equity of 3.07%. The company had revenue of $95.60 million for the quarter, compared to analyst estimates of $89.71 million. During the same period in the prior year, the business earned $0.04 EPS. The firm’s quarterly revenue was up 50.8% on a year-over-year basis. Equities research analysts forecast that NeoGenomics will post 0.18 earnings per share for the current year.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Read More: Equity Income
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.